2024-07-11 14:48:34 ET
Summary
- An interim futility analysis by the DSMB of DM199 for patients with AIS in the phase 2/3 ReMEDy2 trial is expected by Q1 of 2025.
- The global acute ischemic stroke therapeutics market size is expected to be worth $14 billion by 2032.
- Proof-of-concept data from a phase 2 study, using DM199 for the treatment of women with pregnancy complications, is expected 1st half of 2025.
- DM199 for pregnancy complications might be ideal because of the ability to potentially be a disease modifying therapy for patients and that it is not expected to cross the placental barrier.
DiaMedica Therapeutics ( DMAC ) is expected to complete enrollment for an interim futility analysis of its phase 2/3 ReMEDy2 clinical trial, using DM199 for the treatment of patients with acute ischemic stroke [AIS]. Enrollment of 144 patients for such an analysis is expected by Q1 of 2025, barring that there are no delays in recruitment. Having said that, this sets up a chance for it to target a very large multibillion-dollar market, where there are no FDA approved therapies. The company is in the process of activating additional trial sites to get this trial enrolled as quickly as possible. Such a move should allow it to reach its target enrollment of 144 patients for the futility analysis by the expected time frame....
Read the full article on Seeking Alpha
For further details see:
DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point